Overview
Speakers
Barbara Laughon
NIH/NIAID, WGND
Richard Hafner
NIAID - Host-Directed Therapy
Ray Chen
Melvin Spigelman
TB Alliance, WGND
Philippe Prokocimer
Dan Johnson
George Drusano
Laura Via
Veronique Dartois
Kenneth Olivier
Meeting Recap
Goals for the Optimization of Oxazolidinone Workshop were to map the landscape of knowledge; plan for a larger meeting in the fall; and identifiy key individuals for participation in the larger meeting and of available data sets for presentation. The only clinical research on oxazolidinones are the NixTB study (linezolid), STREAM study, NExT trial (linezolid). The reason for urgency in discussing oxazolidinones is to fill the pipeline with more regimens involving these compounds. Discussions on which ones should progress and what kind of dosing should be used need to be made.
- AgendaWelcome and OverviewBarbara LaughonCurrent Research QuestionsRichard HafnerExperience with Linezolid in XDR TBMelvin SpigelmanTedizolid as a candidate for tuberculosis therapyPhilippe ProkocimerSutezolid as a candidate for tuberculosis therapyDan JohnsonBridging pre-clinical and clinical development of novel TB regimens: An example employing LinezolidGeorge DrusanoIn vitro and animal model comparative dataLaura ViaResearch experience at RutgersVeronique DartoisExperience with oxazolidinones for non-tuberculosis mycobacteriaKenneth Olivier
Downloads